Daily Newsletter

22 November 2023

Daily Newsletter

22 November 2023

ViCentra, Dexcom and Diabeloop unveil automated insulin delivery system

The automated hybrid closed-loop insulin delivery system from Dexcom, Diabeloop and ViCentra claims to improve users' time in range (TIR) glucose values by 16.7%.

Kiays Khalil November 21 2023

The Holland based company ViCentra who built Kaleido is leveraging technology from DexCom and Diabeloop to deliver the Hybrid Closed Loop system with the lightest insulin patch pump systems for managing type 1 diabetes.

The Hybrid Closed Loop system will deliver insulin using the DBLG1 algorithm which can receive information from the Dexcom G6 Continuous Glucose Monitoring (CGM) sensor. The DBLG1 algorithm is used by more than 10,000 users across Europe and by using real time data it can reduce hypoglycemia by more than 50%.

It will be housed in the Kaleido insulin pump which can be worn as a patch or placed in the user’s pocket and comes with two pumps. With the DBLG1 algorithm it can teach itself to adjust Kaleido’s insulin delivery for an optimised management of type 1 diabetes

Frans Cromme, Chief Executive Officer of ViCentra, said: “Kaleido with DBLG1 and Dexcom G6 improves users’ Time in Range by 16.7%, an achievement that should bring real benefits to people with type 1 diabetes. We are proud to deliver this game changing technology via a beautiful and small device, as we feel people deserve this when they need to rely on a medical device 24/7.”

Stephane Majerus, Chief Executive Officer of Diabeloop added: “This alliance between Diabeloop's algorithm technology and the ViCentra pump aims to offer people with diabetes the benefits of the Kaleido design combined with our highly performing and proven algorithm.”

The Hybrid Closed Loop system is being distributed in Germany, the Netherlands and France by ViCentra.

Can Generative AI transform the medical devices industry?

The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation, which has improved efficiencies and enhanced patient outcomes. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close